Provided by Tiger Trade Technology Pte. Ltd.

Palvella Therapeutics

150.13
-0.2600-0.17%
Post-market: 150.130.00000.00%19:30 EDT
Volume:163.37K
Turnover:24.69M
Market Cap:2.16B
PE:-30.65
High:154.30
Open:152.75
Low:149.98
Close:150.39
52wk High:161.38
52wk Low:53.30
Shares:14.41M
Float Shares:8.40M
Volume Ratio:0.82
T/O Rate:1.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.8978
EPS(LYR):-3.7076
ROE:-46.63%
ROA:-22.05%
PB:9.97
PE(LYR):-40.49

Loading ...

Palvella Therapeutics Q2 Net Loss Widens on Higher Expenses

Reuters
·
Aug 04

Palvella Therapeutics, Inc Q2 EPS USD -1.52

THOMSON REUTERS
·
Aug 04

Earnings Flash (PVLA) Palvella Therapeutics Posts Q2 Net Loss $1.52 a Share, vs. FactSet Est of $1.07 Loss

MT Newswires Live
·
Aug 04

Palvella Net Loss Widens 130.88% to $21.87 Million in Q2 FY26; R&D Expenses More than Doubled to $12.47 Million

Reuters
·
Aug 04

Palvella Therapeutics Q2 EPS $(1.52) Misses $(1.14) Estimate

Benzinga Earnings
·
Aug 04

Press Release: Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Dow Jones
·
Aug 04

Palvella Therapeutics CSO Jeff Martini Presents at FDA Drug Repurposing Workshop

Reuters
·
Jul 30

Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026

GlobeNewswire
·
Jul 28

H.C. Wainwright says Palvella selloff ‘an overreaction’ to FDA’s BTD denial

TIPRANKS
·
Jul 22

Palvella Therapeutics (PVLA) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Jul 22

Analysts Have Conflicting Sentiments on These Healthcare Companies: Palvella Therapeutics (PVLA), Neogen (NEOG) and ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
Jul 22

Palvella Therapeutics selloff a buying opportunity, says BTIG

TIPRANKS
·
Jul 21

U.S. Small Caps Decrease; Palvella Therapeutics Falls Furthest

Dow Jones
·
Jul 21

Palvella Therapeutics falls -9.0%

TIPRANKS
·
Jul 20

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Armata Pharmaceuticals (ARMP)

TIPRANKS
·
Jul 20

Palvella Therapeutics COO Kathleen Goin Disposes of 4,302 Common Shares Worth $642,194.57

Reuters
·
Jul 18

Palvella Therapeutics Highlights Growth Plans and QTORIN Progress

TIPRANKS
·
Jul 15

Palvella Therapeutics Director Matthew Pauls Files Initial Beneficial Ownership Statement

Reuters
·
Jul 02

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bio-Techne (TECH), Concentra Group Holdings Parent, Inc. (CON) and Palvella Therapeutics (PVLA)

TIPRANKS
·
Jul 01

Palvella Therapeutics Adds Industry Veteran to Board

TIPRANKS
·
Jun 30